Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Total Liabilities (2016 - 2025)

Celldex Therapeutics has reported Total Liabilities over the past 16 years, most recently at $55.8 million for Q4 2025.

  • Quarterly results put Total Liabilities at $55.8 million for Q4 2025, up 23.12% from a year ago — trailing twelve months through Dec 2025 was $55.8 million (up 23.12% YoY), and the annual figure for FY2025 was $55.8 million, up 23.12%.
  • Total Liabilities for Q4 2025 was $55.8 million at Celldex Therapeutics, up from $50.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for CLDX hit a ceiling of $55.8 million in Q4 2025 and a floor of $21.8 million in Q2 2023.
  • Median Total Liabilities over the past 5 years was $31.1 million (2024), compared with a mean of $32.4 million.
  • Biggest five-year swings in Total Liabilities: soared 70.05% in 2022 and later tumbled 42.5% in 2023.
  • Celldex Therapeutics' Total Liabilities stood at $25.2 million in 2021, then increased by 5.37% to $26.5 million in 2022, then surged by 37.41% to $36.5 million in 2023, then rose by 24.36% to $45.3 million in 2024, then rose by 23.12% to $55.8 million in 2025.
  • The last three reported values for Total Liabilities were $55.8 million (Q4 2025), $50.1 million (Q3 2025), and $37.0 million (Q2 2025) per Business Quant data.